Evidence-led target assessment for startups and investors

Biotica Bio turns the same public evidence that big pharma uses into clear, reproducible assessments for target validation, due diligence, and strategy. We use the Open Targets Platform so every narrative is grounded in data—and you can re-run or audit it as evidence updates.

Why Open Targets. The Platform is the same integrated, evidence-based resource that industry and academia use: targets, diseases, drugs, and scored associations in one place. Public, traceable, and reproducible—so your story is credible and updatable. More on the platform →

For startups: Investor-ready target narratives, partner and BD discussions, and pipeline prioritisation—without guessing. See startup-focused support →

For investors: Evidence-led due diligence on targets and pipelines, portfolio monitoring, and screening in new therapeutic areas. Same data, synthesised for deal speed. See investor-focused support →

See an example assessment — Our full BRCA2 oncology target report shows what you get: biology, disease associations, druggability, safety, and strategic synthesis.

Explore all example deliverables or request a scoped proposal.

For background on strategic approach and operator perspective, see John Round and Decision frameworks.

---

Powered by Open Targets. Interpretation and strategy by Biotica Bio.